Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > Press > CombiMatrix Corporation Reports Third Quarter 2007 Financial Results

CombiMatrix Corporation (Nasdaq:CBMX) today reported its unaudited financial results for the third quarter of 2007.

CombiMatrix Corporation Reports Third Quarter 2007 Financial Results

MUKILTEO, WA | Posted on October 24th, 2007

"We are pleased to have completed our split-off from Acacia Research Corporation, and we wish them well as we establish our identity as an independent company focused on personalized medicine. To that end, our diagnostics business continues to grow. We have launched several microarray diagnostics products, and will continue to introduce additional array based diagnostics. Already we have the broadest portfolio of array based diagnostics products of any microarray company, and the number of patients that have benefited from our tests is growing," commented Dr. Amit Kumar, President and CEO of CombiMatrix Corporation.

"For the third quarter of 2007, we achieved revenues of $1,681,000 which represents a 26% increase over the second quarter of 2007 and a 9% decrease from the third quarter of 2006. The decrease relative to 2006 was expected as we made a significant strategic shift in our commercial focus early in 2007 from selling R&D products to researchers to selling diagnostic products and services to physicians, patients and reference laboratories. The change in strategy enables us to allocate resources to our diagnostics business, while facilitating reduced operating costs. Consequently, our net cash burn for the third quarter of 2007 was $2,289,000, which represents a 16% reduction in net cash burn incurred during the second quarter of 2007 and a 39% reduction in net cash burn incurred during the third quarter of 2006," concluded Dr. Kumar.

Operating Results

Revenues for the third quarter of 2007 were $1,681,000 versus $1,336,000 for the second quarter of 2007 and $1,844,000 in the comparable 2006 period. Third quarter 2007 revenues were comprised of $627,000 in government contact revenues and $1,054,000 in CustomArray(tm) product, equipment and service revenues, including diagnostic services. Third quarter 2006 revenues were comprised of $725,000 of government contract revenues and $1,119,000 of CustomArray(tm) product, equipment and service revenues.

Operating expenses for the third quarter of 2007 were $5,571,000 versus $7,195,000 in the comparable 2006 period. Operating expenses included research and development and marketing, general and administrative expenses of $1,924,000 and $2,167,000, respectively, versus $2,819,000 and $2,661,000, respectively, in the comparable 2006 period. Included in these amounts were non-cash stock compensation charges totaling $1,427,000 in the third quarter of 2007 versus $588,000 in the comparable 2006 period.

The third quarter 2007 net loss was $3,433,000 versus $4,327,000 in the comparable 2006 period. These results included non-cash gains of $290,000 and $913,000, respectively, related to the adjustment of the Company's long-term warrant liability to fair value. Excluding the effects of the warrant liability adjustments, our third quarter net loss improved by $1,517,000, or 29% as compared to the net loss for the comparable 2006 period.

Financial Position

Total assets were $38,443,000 as of September 30, 2007 compared to $44,213,000 as of December 31, 2006. Cash, cash equivalents and short-term investments totaled $10,508,000 as of September 30, 2007 compared to $14,341,000 as of December 31, 2006.

A conference call been scheduled for today. The presentation and Q&A session will start at 1:30 p.m. Pacific Time (4:30 p.m. Eastern).

To listen to the presentation by phone, dial 1-800-704-9804 for domestic callers and 1-404-920-6604 for direct dial or international callers. All callers will need to provide the participant code 478994# (478994 followed by the # key). A replay of the audio presentation will be available for 30 days using the same dial-in numbers, but the participant code for the recorded playback is 276886# (276886 followed by the # key).

The call is being webcast live and can be accessed at CombiMatrix's website at , in the Investor section.


About CombiMatrix Corporation
CombiMatrix Corporation is a diversified biotechnology company that develops and sells proprietary technologies, products and services in the areas of drug development, genetic analysis, molecular diagnostics, nanotechnology research, defense and homeland security, as well as other potential markets where our products and services could be utilized. The technologies we have developed include methods to produce DNA arrays for use in identifying and determining the roles of genes, gene mutations and proteins. These technologies have a wide range of potential applications in the areas of genomics, proteomics, biosensors, drug discovery, drug development, diagnostics, combinatorial chemistry, material sciences and nanotechnology.

Additional information about CombiMatrix Corporation is available at .

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995

This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the recent economic slowdown affecting technology companies, our ability to successfully develop products, rapid technological change in our markets, changes in demand for our future products, legislative, regulatory and competitive developments and general economic conditions. Our Annual Report on Form S-1, recent and forthcoming Quarterly Reports on Form 10-Q, recent Current Reports on Forms 8-K and 8-K/A, and other SEC filings discuss some of the important risk factors that may affect our business, results of operations and financial condition. We undertake no obligation to revise or update publicly any forward-looking statements for any reason.

                       COMBIMATRIX CORPORATION
       (In thousands, except share and per share information)


	                            Sept. 30,      Dec. 31,
	                               2007          2006
                                     --------      --------
 Total cash, cash equivalents
  and short-term investments	     $ 10,508      $ 14,341
                                     ========      ========  
 Total assets	                     $ 38,443      $ 44,213
                                     ========      ========
 Total liabilities                   $  2,700      $ 11,399
                                     ========      ========
 Total equity                        $ 35,743      $ 32,814
                                     ========      ========


                          Three Months Ended      Nine Months Ended
                            September 30,            September 30,
                        ---------------------   ---------------------
                           2007        2006        2007        2006
                        ---------   ---------   ---------   ---------
   agreements           $      62   $      63   $     187   $      63
  Government contracts        627         725       1,855       1,563
  Service contracts           164          88         386         205
  Products                    828         968       1,726       3,050
                        ---------   ---------   ---------   ---------
   Total revenues           1,681       1,844       4,154       4,881
                        ---------   ---------   ---------   ---------

 Operating expenses:
  Cost of government
   contract revenues          593         684       1,768       1,476
  Cost of product sales       307         412         858         973
  Research and
   development expenses     1,924       2,819       4,874       7,380
  Marketing, general and

   expense                  2,167       2,661       6,956       9,691
  Patent amortization
   and royalties              332         366         994       1,075
  Equity in loss of
   investees                  248         253         770         786
                        ---------   ---------   ---------   ---------
   Total operating
    expenses                5,571       7,195      16,220      21,381
                        ---------   ---------   ---------   ---------
   Operating loss          (3,890)     (5,351)    (12,066)    (16,500)
                        ---------   ---------   ---------   ---------

 Other income (expense):
  Interest income             167         111         448         429
  Loss on sale of
   interest in
   subsidiary                  --          --          --         (84)
  Warrant gains               290         913       2,523         663
                        ---------   ---------   ---------   ---------
   Total other income         457       1,024       2,971       1,008
                        ---------   ---------   ---------   ---------

 Loss from operations
  before income taxes      (3,433)     (4,327)     (9,095)    (15,492)
 Benefit for income
  taxes                        --          --          --          34
                        ---------   ---------   ---------   ---------
 Net loss               $  (3,433)  $  (4,327)  $  (9,095)  $ (15,458)
                        =========   =========   =========   =========

 Basic and diluted net
  loss per share        $   (0.57)              $   (1.52)
                        =========               =========

 Basic and diluted
  weighted average
  common shares
  outstanding           5,990,189               5,990,189
                        =========               =========

For more information, please click here

CombiMatrix Corporation
Investor Relations
Amit Kumar
(425) 493-2000
Fax: (425) 493-2010

Copyright © PrimeNewswire

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press


Extracellular vesicles could be personalized drug delivery vehicles March 15th, 2018

Department of Materials Test Engineering (WPT) at TU Dortmund University uses Deben CT5000TEC stage to perform X-ray micro-tomography experiments for better understanding of damage progression in composite materials March 13th, 2018

Scientists Use Nanotechnology to Detect Molecular Biomarker for Osteoarthritis March 13th, 2018

Polymer nanoparticle shows ability to locate and treat breast tumors March 13th, 2018


GLOBALFOUNDRIES Launches RF Ecosystem Program to Accelerate Time-to-Market for Wireless Connectivity, Radar and 5G Applications: RFWave Partner Program expands the ecosystem and enables faster product deployment on GFs RF technology platforms March 20th, 2018

Monocrystalline silicon thin film for cost-cutting solar cells with 10-times faster growth rate fabricated: Controlling nano surface roughness of porous silicon March 20th, 2018

Unexpected effect could lead to lower-power memory, computing devices March 17th, 2018

Imaging technique pulls plasmon data together: Rice University scientists' hyperspectral method analyzes many plasmonic nanoparticles in an instant March 16th, 2018

Financial Reports

180 Degree Capital Corp. Reports Net Asset Value per Share of $2.60 as of December 31, 2017; A Decrease of 3.0% From Prior Quarter and an Increase of 11.1% From December 31, 2016 February 27th, 2018

Arrowhead Pharmaceuticals to Webcast Fiscal 2018 First Quarter Results February 3rd, 2018

Nanometrics Announces Preliminary Results for the Third Quarter of 2017: Quarterly Results Impacted by Delays in Revenue Recognition on Multiple Systems into Japan October 12th, 2017

Arrowhead Pharmaceuticals to Webcast Fiscal 2017 Third Quarter Results July 27th, 2017

The latest news from around the world, FREE

  Premium Products
Only the news you want to read!
 Learn More
Full-service, expert consulting
 Learn More

Nanotechnology Now Featured Books


The Hunger Project